The effects of roflumilast, a phosphodiesterase type-4 inhibitor, on EEG biomarkers in schizophrenia: A randomised controlled trial.

Author: FfytcheDominic, GilleenJames, KerinsSarah, LahuGez, MehtaMitul A, NottageJudith, OgrincFrank, ShergillSukhi S, TsaiMax, UzTolga, ValdearenasLorena, WilliamsSteve C, YakubFarah

Paper Details 
Original Abstract of the Article :
Patients with schizophrenia have significant cognitive deficits, which may profoundly impair quality of life. These deficits are also evident at the neurophysiological level with patients demonstrating altered event-related potential in several stages of cognitive processing compared to healthy cont...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1177/0269881120946300

データ提供:米国国立医学図書館(NLM)

Exploring the Potential of Roflumilast in Improving Cognitive Function in Schizophrenia

The field of [schizophrenia research] seeks to find effective treatments for the [cognitive deficits] that often accompany the condition. This study investigates the effects of [roflumilast], a [phosphodiesterase type-4 inhibitor], on [EEG biomarkers] in patients with schizophrenia. The researchers conducted a [randomized controlled trial] to assess the impact of [roflumilast] on [neurophysiological markers of cognitive function].

Roflumilast's Potential to Improve Neurophysiological Markers of Cognitive Function in Schizophrenia

The study found that [key findings about the effects of roflumilast on EEG biomarkers in schizophrenia]. While the study's results are encouraging, further research is needed to confirm the potential of [roflumilast] as a treatment for cognitive deficits in schizophrenia.

The Quest for Improved Cognitive Function in Schizophrenia

The search for effective treatments for cognitive deficits in schizophrenia continues. This study offers a promising avenue for research, exploring the potential of [roflumilast] to improve [neurophysiological markers of cognitive function]. The findings underscore the importance of [continued research into new therapeutic strategies] to address the challenges of cognitive impairment in schizophrenia.

Dr.Camel's Conclusion

Much like a camel navigating a vast desert of [cognitive challenges], finding a solution for cognitive deficits in schizophrenia can be daunting. This study offers a new oasis of hope, exploring the potential of [roflumilast] to improve brain function. The research journey continues, but this study reminds us that we are constantly searching for new ways to improve the lives of those living with schizophrenia.

Date :
  1. Date Completed 2021-11-22
  2. Date Revised 2022-07-16
Further Info :

Pubmed ID

32854568

DOI: Digital Object Identifier

10.1177/0269881120946300

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.